3 R D F E B R U A R Y 2 0 1 6

Team

•  Founders:-RitaVentura-EvaLourenço- ChristopherMaycock-Basedon15yearsofacademicresearch

•  Businessdevelopmentteam:-PedroVilarinho,COTECPortugal- FilipeAguiar,73100–Infraventus

-  FoundedonNovember2013

-  Investor:SetentaeTrêsMileCem,Lda.

ExtremoChem is a start-up company aiming at thedevelopment and commercialisa=on of chemicallysynthesised novel excipients for the stabilisa=on ofbiologics.

Problem/Opportunity

Problem/Opportunity

Ac=veProtein Inac=veProtein

HeatandcoldpHstressShaking

Currentsolu=on:coldchain

CerSfiedcontainer

Distributors

Currentsolu=onissues:

temperatureexcursions

Degrada=on-lossofefficacyandsafety

Manufacturers

Pa=ent

“Improvedthermostabilityofvaccinesisanareaofinterestfor

us”

SeniorDirectorExternalScienSficAffairs,Merck&Co.,USA

Marketneed

Oursolu=on

Archaeoglobusfulgidus

Hydrothermalvents

•  ChemicallysynthesisedanaloguesofproteinstabilisingnaturalcompoundswithimprovedstabilisaSonproperSes

Oursolu=on

STABILISATIONOFBIOPHARMACEUTICALS

Ac=veProtein Ac=veProtein

ChemicalCompound

HeatandcoldpHstressShaking

ValueProposi=on

SynthesisofnewcompoundsforstabilisaSonofbiopharmaceuScalsoverawiderrangeof

temperatures

PHARMACEUTICALINDUSTRY

Biopharmaceu=calsefficacyandsafetyguaranteedallovertheworld

•  ThecostsofcoldchainfailureareesSmatedtobe€5b

•  Spin-offoftheImperialCollegeLondon,2007

•  Excipientmixturederivedfromseedsandcustomisedtoeachvaccine-undertesSng

•  PrivatecompanybasedinCambridge,Massachuse]s,foundedin2001

•  LiposomeencapsulaSonofvaccine-underclinicaltrials

Compe==on

Developmentstatus

ü  Caninsulin–Porcineinsulin,forveterinaryuseü  Lantus,HumulinRegular,Actrapid,InsumanRapid,

InsumanBasal,HumulinNpH,Insulatard-HumanInsulin

ü  CervarixandGardasil–Humanpapilomavirusvaccineü  Erythropoie=n–Human,recombinant,CHOcellsü  NorditropinSimpleXx–Somatropine,humangrowth

hormoneü  Humira–monoclonalanSbody,autoimunediseases

•  Stabilisa=onofcommerciallyavailablebiopharmaceu=calsinthepresenceofExtremoChemcompounds

Developmentstatus

•  StabilisaSonofbiopharmaceuScalsatroomtemperatureupto45daysinthepresenceofExtremoChemcompounds

•  PrevenSonofbiopharmaceuScalaggregaSoncausedbypHstressandshaking-improvementofproduc=onyieldsinthepresenceofExtremoChemcompounds

•  Degrada=onoftheproteinswithoutaddedcompounds

•  Thebiologicalac=vityofthetestedproteinsinthepresenceofourcompoundsremainedthesame

IPProtec=on

•  USPatentsubmiWedduring2014:Hexosederiva4ves,prepara4onandusesthereof

•  IPLegaladvisers:Cooper&DunhamLLP–NewYork

•  PCTapplicaSonunderpreparaSon

•  NewIPunderprepara=on

Businessmodel

•  Co-developmentforeachdifferentindicaSonwithrelevantpharmaceuScalcompanies

Op=misedformula=onforthestabilisa=onoftheAc=vePrincipleIngredients(API’s)

•  Revenuegeneratedthroughlicensing

Roadmap

2014 2015 2016 2017 2018 2019 ...

IP

Services/Colabora=ons

Insulins

R&D

2002…

Vaccines

Monoclonalan=bodies&Epoe=ns

EMA

ToxicityTests

FDA&IPEC

Summary

•  ExtremoChemisatechbasedstart-up

• CommercialisaSonofnewexcipients–distribuSonofbiopharmaceuScalswithouttheneedofcoldchain

• Newstabilisersforimprovementofbiopharmaceu=calproduc=onyieldsduringdownstreamprocessing

•  Ac=veandsafebiopharmaceuScalsallovertheworld

•  Addressesarecognisedunmetmarketneed

StableBiopharmaceuScalsforahealthyworld!

Thankyouforyoura]enSon!

RitaVentura,rita.ventura@extremochem.comEvaLourenço,eva.lourenco@extremochem.com

ChristopherMaycock,chris.maycock@extremochem.comPedroVilarinho,pedro.vilarinho@cotec.pt

FilipeAguiar,filipe.aguiar@infraventus.com